Our ELP platform technology is a growth engine for additional medicines for cardiovascular diseases. It offers the benefits of extended half-life, enhanced usability and simple manufacturing.
Our proprietary technology platform is based on recombinant biopolymers called elastin-like polypeptides (ELPs), which comprise individual building blocks derived from a five-amino acid repeat motif found in the human protein elastin. This five-amino acid motif is repeated multiple times to form the ELP biopolymer.
Our ELP technology extends the circulating half-life of proteins and peptides and also provides a sustained-release mechanism, resulting in exposure of active molecules for periods of a week or longer from a single subcutaneous injection.
Our strategy is to apply our ELP technology to proteins and peptides with well-characterized therapeutic activities but suboptimal half-lives to improve their pharmacokinetics, enable their use as pharmaceutical products and allow for more convenient dosing regimens.
